Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 15/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721914 | 0.93 | GPR119 (0.46) | GPR119TBK1S1PR1 | |
| SCHEMBL4720626 | 0.92 | S1PR1 (0.42) | TNNI3KGPR119LIMK2TBK1S1PR1 | |
| SCHEMBL4721660 | 0.91 | GPR119 (0.40) | GPR119LIMK2TBK1S1PR1 | |
| SCHEMBL4721883 | 0.91 | CDK1 (0.40) | GPR119LIMK2TBK1S1PR1S1PR3 | |
| SCHEMBL4722994 | 0.90 | GPR119 (0.39) | TNNI3KGPR119LIMK2TBK1S1PR1 | |
| SCHEMBL389589 | 0.89 | GPR119 (0.51) | GPR119LIMK2TBK1 | |
| SCHEMBL4723270 | 0.88 | LCK (0.40) | GPR119 | |
| SCHEMBL4718690 | 0.86 | TBK1 (0.38) | GPR119TBK1S1PR1 | |
| SCHEMBL27939280 | 0.85 | GPR119 (0.44) | TNNI3KGPR119TBK1S1PR1 | |
| SCHEMBL4723148 | 0.85 | GPR119 (0.41) | GPR119TBK1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756084-B1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-11-26 | — | — | EP | claimed |